Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC reduced its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 31.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,727 shares of the medical equipment provider’s stock after selling 15,033 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Zimmer Biomet were worth $3,217,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Grove Bank & Trust increased its position in shares of Zimmer Biomet by 431.6% during the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 328 shares during the period. Northside Capital Management LLC boosted its holdings in Zimmer Biomet by 144.4% in the fourth quarter. Northside Capital Management LLC now owns 140,226 shares of the medical equipment provider’s stock valued at $12,609,000 after purchasing an additional 82,844 shares during the period. Wilsey Asset Management Inc. acquired a new position in Zimmer Biomet during the 4th quarter worth $32,439,000. Sage Capital Advisors llc increased its holdings in Zimmer Biomet by 27.2% during the 4th quarter. Sage Capital Advisors llc now owns 11,702 shares of the medical equipment provider’s stock worth $1,052,000 after purchasing an additional 2,502 shares during the period. Finally, Boltwood Capital Management raised its position in Zimmer Biomet by 3.9% in the 4th quarter. Boltwood Capital Management now owns 3,866 shares of the medical equipment provider’s stock valued at $348,000 after purchasing an additional 144 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 1.9%

ZBH stock opened at $90.26 on Wednesday. The stock has a market cap of $17.66 billion, a P/E ratio of 25.50, a PEG ratio of 1.81 and a beta of 0.58. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. Zimmer Biomet Holdings, Inc. has a twelve month low of $84.59 and a twelve month high of $114.44. The company’s 50 day moving average is $92.09 and its two-hundred day moving average is $93.81.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.04. The business had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Insider Activity

In other news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the sale, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. The Goldman Sachs Group cut shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price on the stock. in a report on Friday, January 9th. Weiss Ratings cut shares of Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, March 23rd. Citigroup restated a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. Finally, Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.